Surgical Transversus Abdominis Plane Block in Pediatric Patients

Efficacy of Surgical Transversus Abdominis Plane Block for Postoperative Pain Relief Following Abdominal Surgery in Pediatric Patients.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01548027

Acronym

TAP

Enrollment

Registered

2012-03-08

Start date

2012-07-31

Completion date

2014-07-31

Last updated

2014-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child

Keywords

TAP block, postoperative analgesia

Brief summary

The objective of this study to determine the effect of surgical transversus abdominis plane block and local infiltration for postoperative pain control in major abdominal surgery compare with control group.

Detailed description

Most children experience postoperative pain after major abdominal surgery. They may have ineffective ventilation, following atelectasis and pneumonia if receive inadequate pain management. There are several methods used for pain relief such as epidural block, intravenous analgesia with local infiltration, transversus abdominis plane (TAP) block by ultrasound guided and surgical TAP block. Therefore, the investigators would like to compare the effectiveness of postoperative pain control with TAP block. However, TAP block in children need experience and ultrasound. The investigators decided to do surgical TAP block performing by inject from peritoneum point to skin instead.

Interventions

PROCEDURELocal infiltration group

patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.

PROCEDURETAP block

Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months

OTHERNo intervention

No intervention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

No minimum to 15 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age \< 15 year 2. ASA I-III 3. Abdominal surgery : all upper abdomen and lower abdomen which would have midline incision 4. Elective surgery

Exclusion criteria

1. Allergic to Lidocaine or bupivacaine 2. Delayed development 3. Major abdominal surgery within 2 year

Design outcomes

Primary

Measure	Time frame	Description
opioids consumption	24 hours	total opioids consumption in first 24 hours postoperatively

Secondary

Measure	Time frame
Time to first analgesic	24 hr

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026